Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized Study of Three Subcutaneous Bortezomib-based Consolidation Treatments for Patients Completing Induction Therapy and Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Trial Profile

A Phase II Randomized Study of Three Subcutaneous Bortezomib-based Consolidation Treatments for Patients Completing Induction Therapy and Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2018

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 13 Aug 2018 Status changed from active, no longer recruiting to completed.
    • 06 Jul 2016 Planned End Date changed from 1 Nov 2013 to 1 May 2018.
    • 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top